ELEKTA, a global medical technology company dedicated to oncology and neuroscience clinical advancements, is seeking to fill approximately 80 new positions at its Crawley plant.
Recently, the company announced it had achieved CE Marking for a new cancer treatment innovation called Agility™, a revolutionary new form of multi-leaf collimator (MLC), a device that precisely shapes radiation beams to tumour targets.
These new technical positions at Elekta will support the manufacturing and further refinement of this novel cancer treatment technology, and reinforces the UK’s goals of increasing scientific innovation and employment opportunities.
Elekta’s Crawley plant workforce has risen from 400 to 680 since 2009
In the U.K. supply chain, Elekta supports approximately 1,000 manufacturing jobs
Elekta was awarded the 2012 Queens Award for Enterprise in International Trade
Growth in exports from Elekta Crawley is calculated at 131% over the last six years
Elekta Crawley pioneered the digital linear accelerator (radiation treatment machine) 30 years ago.